Meanwhile, CASGEVY, the company's gene therapy for sickle cell disease, has begun generating revenue, albeit with a slow ramp-up expected. Over 50 treatment centers have been activated globally ...

The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston Children's Hospital—have been game-changing for the patients who have ...

A product recall of Lay's Classic Potato Chips is now at the highest risk level for a batch that may contain undeclared milk ingredients. The chips involved weren't shipped to Kentucky, according ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

When the FDA approved Casgevy as the first therapy using CRISPR gene-editing technology in 2023, sickle cell anemia patients and their caregivers were astonished, hopeful, and concerned. It had been ...

The newest gene therapy treatment, Casgevy, treats sick cell disease and transfusion-dependent beta thalassemia. Its addition means that CHLA provides the most cell and gene therapy treatments for ...

The company recently unveiled several strategic priorities related to the ongoing launch of Casgevy, a one-time gene therapy treatment for blood disorders. Indeed, a breakthrough in this space could ...

In 2023, Vertex earned approval for Casgevy, a gene-editing treatment for two rare blood-related conditions with very few treatment options. Vertex Pharmaceuticals didn't create Casgevy itself ...

Secondly, McKesson’s dedicated business unit, InspiroGene, partnered with Vertex Pharmaceuticals to expand distribution options for CASGEVY, the first CRISPR-based gene-editing therapy approved ...

For example, the FDA-approved CRISPR-Cas9-based therapy Casgevy, designed to treat sickle cell disease, provides life-changing potential but comes at a staggering one-time cost of $2.2 million.